• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

乳腺癌：唑来膦酸——不仅仅是一种骨药物。

Breast cancer: Zoledronic acid--more than just a bone drug.

机构信息

University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Center Avenue, Pittsburgh, PA 15232, USA.

出版信息

Nat Rev Clin Oncol. 2014 Oct;11(10):564-5. doi: 10.1038/nrclinonc.2014.152. Epub 2014 Sep 9.

DOI:10.1038/nrclinonc.2014.152
PMID:25200411
Abstract

Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although negative,highlight the potential benefit of treatment with zoledronic acid in postmenopausal women with high-risk early stage breast cancer.

摘要

几项临床试验研究了双膦酸盐作为早期乳腺癌辅助治疗的抗肿瘤作用。其中，AZURE 试验的结果虽然为阴性，但强调了唑来膦酸治疗绝经后高危早期乳腺癌患者的潜在获益。

相似文献

1
Breast cancer: Zoledronic acid--more than just a bone drug.乳腺癌：唑来膦酸——不仅仅是一种骨药物。
Nat Rev Clin Oncol. 2014 Oct;11(10):564-5. doi: 10.1038/nrclinonc.2014.152. Epub 2014 Sep 9.
2
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.早期乳腺癌患者的辅助唑来膦酸治疗：AZURE（BIG 01/04）随机、开放标签、3 期临床试验的最终疗效分析。
Lancet Oncol. 2014 Aug;15(9):997-1006. doi: 10.1016/S1470-2045(14)70302-X. Epub 2014 Jul 15.
3
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.MAF 扩增对早期乳腺癌辅助唑来膦酸治疗结局的影响：国际、开放标签、随机、对照、III 期 AZURE（BIG 01/04）试验的二次分析。
Lancet Oncol. 2017 Nov;18(11):1543-1552. doi: 10.1016/S1470-2045(17)30603-4. Epub 2017 Oct 13.
4
Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?唑来膦酸治疗早期乳腺癌：是否有定论？
Curr Oncol Rep. 2012 Feb;14(1):35-43. doi: 10.1007/s11912-011-0209-5.
5
AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.AZURE亚组分析显示，唑来膦酸辅助治疗可能使绝经超过5年的乳腺癌患者获益。
Oncology (Williston Park). 2011 Nov 15;25(12):1212-3.
6
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.早期乳腺癌辅助他莫昔芬、来曲唑或来曲唑联合唑来膦酸的骨效应：随机 3 期 HOBOE 研究。
Ann Oncol. 2012 Aug;23(8):2027-2033. doi: 10.1093/annonc/mdr600. Epub 2012 Mar 12.
7
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.唑来膦酸对骨髓中播散肿瘤细胞及生存的影响：一项前瞻性临床试验的结果
BMC Cancer. 2013 Oct 15;13:480. doi: 10.1186/1471-2407-13-480.
8
Zoledronic acid: a review of its use in breast cancer.唑来膦酸：其在乳腺癌治疗中的应用综述
Drugs. 2008;68(18):2661-82. doi: 10.2165/0003495-200868180-00010.
9
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.接受辅助性乳腺癌治疗的绝经后女性癌症治疗引起的骨质流失的管理：Z-FAST更新
Semin Oncol. 2006 Apr;33(2 Suppl 7):S13-7. doi: 10.1053/j.seminoncol.2006.03.022.
10
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.唑来膦酸在接受辅助来曲唑治疗的绝经后早期乳腺癌妇女中的疗效：ZO-FAST 研究的 36 个月结果。
Ann Oncol. 2010 Nov;21(11):2188-2194. doi: 10.1093/annonc/mdq217. Epub 2010 May 5.

引用本文的文献

1
The Use of Hydroxyapatite Loaded with Doxycycline (HADOX) in Dentoalveolar Surgery as a Risk-Reduction Therapeutic Protocol in Subjects Treated with Different Bisphosphonate Dosages.将载有强力霉素的羟磷灰石（HADOX）用于牙牙槽外科，作为不同双膦酸盐剂量治疗的受试者的风险降低治疗方案。
Medicina (Kaunas). 2022 Dec 27;59(1):46. doi: 10.3390/medicina59010046.
2
Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.包裹唑来膦酸的自组装纳米颗粒可抑制间充质基质细胞的分化、迁移和促血管生成因子的分泌及其与前列腺癌细胞的相互作用。
Oncotarget. 2017 Jun 27;8(26):42926-42938. doi: 10.18632/oncotarget.17216.
3

本文引用的文献

1
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.早期乳腺癌患者的辅助唑来膦酸治疗：AZURE（BIG 01/04）随机、开放标签、3 期临床试验的最终疗效分析。
Lancet Oncol. 2014 Aug;15(9):997-1006. doi: 10.1016/S1470-2045(14)70302-X. Epub 2014 Jul 15.
2
Bisphosphonates in breast cancer.乳腺癌中的双磷酸盐类药物。
Int J Cancer. 2015 Aug 15;137(4):753-64. doi: 10.1002/ijc.28965. Epub 2014 May 20.
3
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.通过白花丹醌和唑来膦酸对磷酸腺苷进行结构模拟，在乳腺癌模型中竞争性靶向JNK/Erk，协同减弱破骨细胞生成。
Cell Death Dis. 2016 Feb 11;7(2):e2094. doi: 10.1038/cddis.2016.11.
4
Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.在VX2兔肿瘤模型中，αvβ3靶向的Sn2脂肪酶不稳定烟曲霉毒素前药纳米颗粒与唑来膦酸的联合治疗。
Nanomedicine. 2016 Jan;12(1):201-11. doi: 10.1016/j.nano.2015.10.003. Epub 2015 Oct 27.
唑来膦酸（唑来膦酸盐）用于接受辅助来曲唑治疗的绝经后早期乳腺癌女性（ZO-FAST 研究）：最终 60 个月结果。
Ann Oncol. 2013 Feb;24(2):398-405. doi: 10.1093/annonc/mds277. Epub 2012 Oct 9.
4
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.口服氯膦酸盐辅助治疗可手术乳腺癌（美国国家癌症研究所外科辅助治疗和研究组协议 B-34）：一项多中心、安慰剂对照、随机试验。
Lancet Oncol. 2012 Jul;13(7):734-42. doi: 10.1016/S1470-2045(12)70226-7. Epub 2012 Jun 14.
5
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.Z-FAST 试验的最终 5 年结果：接受来曲唑治疗的绝经后乳腺癌患者使用唑来膦酸辅助治疗可维持骨量。
Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10.
6
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.颌骨骨坏死的发生率、风险因素和结局：三例有对照的 III 期临床试验对癌症伴骨转移患者的综合分析
Ann Oncol. 2012 May;23(5):1341-1347. doi: 10.1093/annonc/mdr435. Epub 2011 Oct 10.
7
Potential anticancer properties of bisphosphonates: insights from preclinical studies.双膦酸盐的潜在抗癌特性：临床前研究的新见解。
Anticancer Agents Med Chem. 2012 Feb;12(2):102-13. doi: 10.2174/187152012799014977.
8
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.辅助内分泌治疗联合唑来膦酸治疗早期乳腺癌绝经前妇女：ABCGS-12 随机试验的 62 个月随访结果。
Lancet Oncol. 2011 Jul;12(7):631-41. doi: 10.1016/S1470-2045(11)70122-X. Epub 2011 Jun 5.